4.5 Article

A European care bundle for management of ventilator-associated pneumonia

Journal

JOURNAL OF CRITICAL CARE
Volume 26, Issue 1, Pages 3-10

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.jcrc.2010.04.001

Keywords

Ventilator-associated pneumonia; Care bundles; Diagnosis; Therapy

Funding

  1. Pfizer
  2. Johnson Johnson
  3. Merck
  4. Astra Zeneca
  5. Wyeth
  6. Roche Diagnostics
  7. Becton Dickinson
  8. Chiron-Novartis
  9. GeneOhm
  10. BioMerieux
  11. Bayer
  12. Sanofi-Aventis
  13. Intermune
  14. Daiichi
  15. Astellas
  16. Glaxo-SmithKline
  17. Boehringer Ingelheim
  18. Wyeth International
  19. Instituto Salud Carlos III [FISS 06/0060]
  20. IISPV

Ask authors/readers for more resources

Background: Although there is a wealth of guidance concerning the management of patients with ventilator-associated pneumonia (VAP), compliance with recommendations concerning optimal treatment practices is highly variable. Methods: This document presents a comprehensive care bundle package addressing all aspects of VAP diagnosis and treatment in an attempt to promote guideline-compliant practices. Uniquely, the development of these care bundles used a formalized method to assess the supporting data, based on multicriteria decision analysis. Results: This system allowed the numerous VAP management parameters identified from recent European guidelines to be ranked according to defined criteria. The resulting VAP care bundles are (a) diagnosis: early chest x-rays within 1 hour, immediate reporting of respiratory secretions Gram staining, and (b) therapy: immediate treatment, empiric therapy based on local pathogens and risk factors, de-escalation, assessment of response within 72 hours, and short therapy duration if feasible. Conclusion: Adoption of these care bundles should rationalize VAP management practices and facilitate the development of consistent and guideline-compliant care processes. (C) 2011 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available